JNJ-61186372: The anti-tumor activity of JNJ-61186372, a c-Met and EGFR bispecific antibody, was investigated in in vitro and in vivo studies involving NSCLC tumor models, and showed strong ability to reduce tumor growth [61,62]. Here, MET is linked to non-small cell lung carcinoma.